

# D.C. DEPARTMENT OF HEALTHCARE FINANCE

Magellan Health Pharmacy Benefits Manager

## NEWS

VOL. 1, ISSUE 1  
SUMMER 2022



June 2022

### Magellan Medicaid DHCF Providers websites

PDL info <https://dc.fhsc.com/> Portal <http://www.dc-pbm.com>

**The DC Medicaid Providers Forum** was held via Zoom on Wed June 15, from 10am to 12 noon, and also on Thursday June 16, from 1pm to 3pm. This meeting featured a discussion by our audit division on e-prescribing and billing requirements, and updates from our MCO Partners. You can view the complete slide decks from this and past presentations here <http://www.dc-pbm.com> Use "Provider" tab > "documents" > "quarterly pharmacy provider forum."

**Greetings** D.C. Medicaid Providers,

We at the Department of Healthcare Finance and Magellan Health PBM would like to take this opportunity to share important announcements to help better serve our patients. We appreciate all you do to provide timely and vital healthcare services and medication therapy to our D.C. Medicaid patient population. Stay tuned for more updates concerning DC Fee for Service Medicaid.

--Charlene Fairfax, Senior Pharmacist  
D.C. Department of Health Care Finance

### Trulicity® "grandfathering" Ends July 1st 2022

**Attention Providers-** Effective March 15, 2022 the PDL status of Trulicity changed to non-preferred, requiring prior authorization. A notice has been circulated to our enrolled DC Medicaid providers, and a grace period extended until July 1, 2022 to give time to change patients to alternative therapy. Preferred agents in this category include Bydureon® Byetta® Ozempic® and Victoza®



**A note on COVID-19 tests** -DC FFS Medicaid is covering COVID-19 Home test kits, which can be billed as a prescription using the provider's NPI. We are monitoring these claims on a weekly basis for appropriate submission, reasonable billing, and trends.

### DC Medicaid Pharmacy and Therapeutics Meeting Preferred Drug List (PDL) Review

The DC Medicaid P & T Committee convened for its quarterly meeting on June 2, 2022. at 2:30 pm via Zoom.

**The following agents had changes in PDL status:**

- Generic tobramycin for Tobi became a preferred agent and Bethkis and Kitabis Pak become non-preferred.
- Spiriva Respimat became a preferred agent.
- Epipen and Epipen Jr became preferred agents.
- Pulmicort Flexhaler became a preferred agent.
- Celecoxib generic became a preferred agent.
- Extended release dexamethylphenidate and extended release clonidine became preferred agents. Focalin XR became non-preferred.

**The next meeting will be held Thursday, September 8th 2022.**